抗糖尿病药物向基因与炎症性肠道疾病的关联:孟德尔的随机化研究
Xiangli Qing1,2, Lin Wang1, Shuangshuang Fang1
1Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Journal of inflammation research
|March 13, 2024
概括
这项研究调查了针对炎症性肠病 (IBD) 的抗糖尿病药物,该研究发现向KCNJ11基因的硫尿素可能会降低克罗恩病 (CD) 风险. 这表明对CD患者有潜在的治疗益处.
科学领域:
- 遗传学和药理学 遗传学和药理学
- 胃肠病学 胃肠病学
- 药物发现 药物发现 药物发现
背景情况:
- 对于有效的炎症性肠病 (IBD) 治疗,存在着未得到满足的需求.
- 观察性研究表明抗糖尿病药物在IBD管理中的潜在治疗作用.
研究的目的:
- 研究抗糖尿病药物对IBD的潜在治疗作用.
- 探索抗糖尿病药物标与IBD风险之间的遗传联系.
主要方法:
- 使用基于总结数据的孟德尔随机化 (SMR) 和两样本的孟德尔随机化 (TSMR).
- 分析了抗糖尿病药物点的血液/结肠和单核酸多态 (SNP) 中的表达定量特征位置 (eQTL).
- 包括IBD,性结肠炎 (UC) 和克罗恩病 (CD) 的大型队列.
主要成果:
- 血液中KCNJ11基因 (硫氨基酸) 的升调与降低CD风险相关 (OR=0.728,P=0.004).
- 通过2型糖尿病 (T2D) 介导的KCNJ11,显示对CD有保护作用 (OR=0.475,P=0.002).
- 在结肠中ABCC8 (甲基) 表达没有显著影响IBD,UC或CD风险.
结论:
- 硫尿素可能会对克罗恩病产生保护作用.
- 研究结果表明,特定的抗糖尿病药物类别对CD管理具有潜在的益处.
- 需要进一步的研究来证实硫氨酸基质在CD治疗中的治疗潜力和安全性.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
Inflammatory Bowel Disease I: Ulcerative Colitis
181
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
181
Drugs for Treatment of Ulcerative Colitis in IBD
139
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
139


